Founded in 2003 with an initial focus on developing diagnostic assays and biotherapeutics, ProteoGenix quickly evolved into a pioneering Contract Research Organization (CRO) and a trusted partner in the biopharma industry. Recognizing the critical role that high-quality antibodies and proteins play in accessing the clinical setting, ProteoGenix leveraged its expertise to improve the success rate of biomolecules reaching Investigational New Drug (IND) applications.
As a service integrator, ProteoGenix guides customers through the entire journey from early discovery to clinical applications. They anticipate the future needs of biomolecules from the get-go, designing development strategies that can navigate the complexities of clinical validation. Their multifaceted approach offers innovative solutions and technologies in six key areas:
- Antibody engineering
- Bioprocess development
- Monoclonal and polyclonal antibody development
- Recombinant protein and antibody production
- Gene synthesis
- Peptide synthesis
ProteoGenix is not just a service provider but also a hub of innovation. Their R&D labs continue to push the envelope, introducing groundbreaking innovations like XtenCHO™, a cell line for transient expression that outperforms ExpiCHO in productivity.
Beyond their services, ProteoGenix offers an extensive catalog of over 200,000 products available through their online shop. This catalog includes antibodies, proteins, ELISA kits, cell separation media, nucleic acid purification kits, and more, all easily searchable via their efficient search engine.
With over 15 years of experience and a solid international reputation, ProteoGenix stands as a major player in the life sciences, committed to enhancing the success rate of clinical applications in the biopharma landscape.